Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-05-17
2011-05-17
Bradley, Christina (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07943572
ABSTRACT:
Methods related to the treatment of diabetes and improving the control of blood glucose levels are provided. In particular, methods are provided for effectively reducing postprandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration. Additionally, methods for effectively reducing post-prandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration along with a long-acting basal insulin.
REFERENCES:
patent: 5352461 (1994-10-01), Feldstein et al.
patent: 5503852 (1996-04-01), Steiner et al.
patent: 5506203 (1996-04-01), Backstrom et al.
patent: 5547929 (1996-08-01), Anderson, Jr. et al.
patent: 5888477 (1999-03-01), Gonda et al.
patent: 5976569 (1999-11-01), Milstein
patent: 6071497 (2000-06-01), Steiner et al.
patent: 6331318 (2001-12-01), Milstein
patent: 6395774 (2002-05-01), Milstein
patent: 6428771 (2002-08-01), Steiner et al.
patent: 6444226 (2002-09-01), Steiner et al.
patent: 6652885 (2003-11-01), Steiner et al.
patent: 6923175 (2005-08-01), Poole et al.
patent: 2004/0062722 (2004-04-01), Gonda et al.
patent: 2004/0182387 (2004-09-01), Steiner et al.
patent: 2005/0153874 (2005-07-01), Cheatham et al.
patent: 2006/0040953 (2006-02-01), Leone-Bay et al.
patent: 2006/0153778 (2006-07-01), Gelber et al.
patent: 2007/0020191 (2007-01-01), Boss et al.
patent: 0220958 (1987-05-01), None
patent: 96/36314 (1996-11-01), None
patent: 99/52506 (1999-10-01), None
patent: WO 01/00654 (2001-01-01), None
Cefalu et al. “Inhaled Human Insulin Treatment in Patients with Type 2 Diabetes Mellitus,” Ann. Int. Med., 2001, 134, 203-7.
Nathan, D.M. et al. “Intensive diabetes treatment and cardiovascular disease in patients with Type 1 diabetes.” New Eng. J. Med. 353:2643-3653, 2005.
Cefalu WT., “Concept, strategies and feasibility of noninvasive insulin delivery”, Diabetes Care 27:239-246, 200.
Cerasi, et al., “Decreased sensitivity of the pancreatic beta cells to glucose in prediabetic and diabetic subjects. A glucose dose-response study”, Diabetes 21(4):224-34, 1974.
Gupta et al., “Contemporary approaches in aerosolized drug delivery to the lung”, J. controlled Research, 17:129-148, 1991.
Heinemann, et al., “Current status of the development of inhales insulin”, Br J Diabetes Vasc Dis, 4:295-301, 2004d.
Leahy, et al., “Beta-ell dysfunction in type II diabetes mellitus”, Curr Opin Endocrinol Diabetes, 2:300-306, 1995.
Lian, et al., “A self-complementary self-assembling microsphere system: application for intravenous delivery of the antiepileptic and neuroprotectant compound felbanate”, J. Pharm Sci 89:867-875, 2000.
Pfeifer MA, et al., “Insulin secretion in diabetes mellitus”, Am J Med, 70:579-88, 1981.
Polonsky, et al., “Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus”, N Eng J Med, 318:1231-39, 1988.
Steiner, S. et al., “Technosphere (TM) /Insulin—proof of concept study with a new insulin formulation for pulmunary delivery”, Exp Clin Endocrinol Diabetes, 110:17-21, 2002.
Edelman, SV., “Type II diabetes mellitus”, Adv Int Med, 43:449-500, 1998.
Kohler, D., et al., “Non-radioactive approach for measuring lung permeability: inhalation of insulin”, Atemw Lungenkrkh, 13:230-232, 1987 (Original German and English translation attached).
Raz, et al., “Pharmacodynamics and pharmacokinetics of dose ranging effects of Oralin versus s.c. regular insulin in Type 1 diabetic patients”, Fourth Annual Diabetes Technology Meeting, Philadelphia, PA 2004.
Raskin, et al., “Continuous Subcutaneous Insulin Infusion and Multiple Daily Injection Therapy are Equally Effective in Type 2 Diabetes”, Diabetes Care, vol. 26, No. 9, pp. 2598-2603, Sep. 2003.
Cheatham, et al., “Desirable dynamics & performance of inhaled Insulin Compared to Subcutaneous Insulin Given at Mealtime in Type 2 Diabetes: A Report from the Technosphere/Insulin Study Group”, pp. 234-235, 2004.
Cernea, et al., “Dose-Response Relationship of Oral Insulin Spray in Healthy Subjects”, Diabetes Care, Vo. 28, No. 6, pp. 1353-1357, Jun. 2005.
Warren, et al., “Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients”, Diabetes Research and Clinical Practice, vol. 66, pp. 23-29, 2004.
Farr, SJ et al. “Pulmonary insulin administration using the AERx(R) system: physiological and physiochemical factors influencing insulin effectiveness in healthy fasting subjects.” Diabetes Tech. Ther. 2:185-197, 2000.
Hussain A and Ahsan F “State of insulin self-association does not affects its absorption from the pulmonary route.” Eur. J. Pharm. Sciences 25:289-298, 2005.
Boss Anders Hasager
Cheatham Wayman Wendell
Bergman Michelle Glasky
Bradley Christina
Cullman Louis C.
K&L Gates LLP
MannKind Corporation
LandOfFree
Superior control of blood glucose in diabetes treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Superior control of blood glucose in diabetes treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Superior control of blood glucose in diabetes treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2702316